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Abstract
IntRoDuctIon
Clinical trials of endovascular intervention for emergent large 
vessel occlusion have revolutionized the management of acute 
ischemic stroke. This has been achieved after more than a 
decade of iteration of various clinical trial paradigms.
We had opined earlier that the design characteristics of the 
positive clinical trial may unduly influence the evolution of 
trial designs for settling unanswered questions, and delay the 
process of evidence generation.[1,2] This phenomenon may 
be a result of a too narrow interpretation of the data from 
clinical trials and in certain cases an outcome of a confluence 
of multiple extraneous factors not directly related to scientific 
evidence in question.
In this article, we present a few restrictions in practice imposed 
by excessive and undesirable extrapolation of evidence from 
clinical trials. In addition, we bring about the “blind-alleys” 
of evidence brought about by premature termination of certain 
clinical trials. We strive to elucidate the issues in the generation 
of meaningful evidence in the paradigm of evidence-based 
medicine when extraneous factors influence the conduct/
conclusion of clinical studies.
altePlase In emeRgent laRge vessel occlusIon
The guideline for intravenous (IV) thrombolysis using alteplase 
has developed from the inclusion and exclusion criteria of 
the NINDS rtPA (National Institute of Neurological Diseases 
and Stroke- tissue plasminogen activator) trial published in 
1995.[3] When the guidelines for IV thrombolysis evolved it 
was quite reasonable that NINDS rtPA trials eligibility criteria 
be followed as closely as possible,[4] as NINDS rPA trial was 
the sole positive trial of the dozen clinical trials that failed to 
show benefit for thrombolysis with alteplase in acute ischemic 
stroke.[5,6]
American Heart Association/American Stroke Association 
(AHA/ASA) guidelines state that alteplase has to be 
administered in any patient who presents with acute ischemic 
stroke within the therapeutic window satisfying the eligibility 
criteria[7] which largely represents the NINDS rtPA trial 
selection criteria. It further states that for the administration 
of alteplase there is no need for any imaging modality beyond 
non-contrast computed tomography (CT) scan. However, it is 
not possible to make a diagnosis of large vessel occlusion based 
on the selection criteria of NINDS rtPA or ECASS III trials; two 
trials that have shown results in favor of IV thrombolysis. The 
guidelines require CT angiography (CTA) for demonstration of 
large vessel occlusion. The clot lysis using alteplase is as low 
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as 30%[8] in visible intracranial occlusion. If the clot length is 
beyond 5 mm the likelihood of clot lysis falls drastically and it 
is negligible if the clot length is more than 8 mm.[9] In many of 
the patients with large clot length and proximal thrombus, IV 
thrombolysis is not only ineffective but may be deleterious as 
the incomplete action of IV thrombolytic agent make the clot 
friable and prone to distal embolism that many times are not 
amenable to thrombectomy. It is a common clinical situation 
that while the proximal thrombus is removed and recanalization 
achieved, the distal thrombus would cause infarcts further 
causing clinical deficits, confounding the improvement effected 
by successful proximal thrombectomy.[10] The insistence of 
administration of alteplase immediately after non-contrast 
CT causes a scenario where ischemic stroke with large vessel 
occlusion due to large clot burden, get IV lytic agent that not 
only is ineffective but may be deleterious to the beneficial 
effects of the definitive treatment of thrombectomy. While 
many would demand a clinical trial to resolve this issue, we 
believe that in centers with good process standards and rapid 
recanalization rates, the decision to give IV thrombolysis 
before thrombectomy in proximal large vessel occlusion should 
be made case-by-case based on the review of CTA. In our view, 
considering direct mechanical thrombectomy in large vessel 
occlusion with a clot size >8 mm makes a strong case based 
on available evidence. The ongoing SWIFT-DIRECT would 
shed light on this issue.[11]
In many nations, the administration of alteplase is protocolized 
making it difficult for the physicians to make a judgment based 
on the local circumstances.
A scientifically reasonable guideline would be to allow the 
physician to go ahead with CTA and determine the future 
course of action incorporating the CTA findings. In most 
centers, a CTA can be done within a matter of 5–10 min. We 
view that insistence of guidelines to demand administration 
of alteplase before vascular imaging is an unreasonable 
imposition of incomplete evidence on the treatment autonomy 
of the physician. However, it is a reasonable policy for 
administering IV alteplase if CTA is not available or the patient 
has to be transferred to another center. Nevertheless, the best 
policy is to have CTA in the first setting when a patient is 
undergoing imaging. This would allow proper therapeutic 
planning and prognostication of the patient’s outcome.
Antiplatelet agent after intravenous thrombolysis
In NINDS rtPA trial aspirin was avoided in the initial 24 h after 
thrombolysis. This stipulation is quite reasonable as most of the 
initial thrombolysis trials showed higher rates of intracerebral 
hemorrhage (ICH). However, after the publication of the 
NINDS rtPA trial, we have experiences of tens of thousands 
of patients who had undergone IV thrombolysis for ischemic 
stroke. In the SITS-MOST registry representing the real-life 
outcome of IV thrombolysis, the incidence of symptomatic 
intracerebral hemorrhage (SICH) is less than 2%. Studies have 
demonstrated that the incidence of ICH after IV thrombolysis 
in a patient on antiplatelet is not high.[12] However, in many 
practice settings, the guideline is applied rigorously that it 
conflicts with the requirements of practices that have evolved 
later. For instance, in endovascular intervention, there are 
situations where it may be needed to apply intracranial stents 
due to conditions like intracranial atherosclerosis. Although 
stenting in ELVO due to intracranial atherosclerosis has not 
been demonstrated as a practice in a controlled trial paradigm, 
the current practice of endovascular intervention many 
times entails such a scenario. The insistence of withholding 
antiplatelet until 24 h would potentially jeopardize the situation 
as the incidence of stent thrombosis is potentially higher than 
that of post thrombolysis ICH following antiplatelet use.
Although many practitioners would forgo the practice 
guidelines in favor of stenting and antiplatelet use, many 
countries where guidelines are protocolized, and various 
components of the treatment are administrated by different 
disciplines, it creates hurdles in the practice.
MELT and Urokinase
The almost “absolutist” interpretation of established evidence 
over an emerging practice is an undesirable phenomenon 
seen in the practice of evidence-based medicine. A similar 
practice was seen when the Middle Cerebral Artery 
Embolism Local Fibrinolytic Intervention Trial (MELT) 
was testing intraarterial (IA) urokinase in Japan between 
2002 and 2005.[13] Japanese investigators had used an 
opportunity window available in Japan as IV tPA was in the 
process of regulatory clearance. However, as the tPA got 
regulatory clearance, the study was terminated despite early 
trends favoring IA urokinase. A meta-analysis combining 
halfway terminated MELT and Prolyse in Acute Cerebral 
Thromboembolism (PROACT) trials had shown benefit in 
favor of IA urokinase.[14] However, the question was not 
pursued further as the relevant agencies were not interested. In 
this instance, “would-be” evidence is suppressed by “emerged” 
evidence by citing regulatory requirements. We consider such 
an interpretation of established evidence as a hindrance to the 
free evolution of scientific evidence in medicine.
We propose that in such scenarios the “effect size” of the 
“emerged evidence” should be compared against the possible 
“effect size” of the “emerging evidence.” For instance, the 
effect size of IV tPA is 13% with a number needed to treat 
of 8 while the effect size of PROACT II from earlier studies 
was 15% with an number needed to treat of 6. The premature 
termination of an endovascular trial like MELT sidestepped 
a whole treatment paradigm and delayed the evolution of 
scientific evidence in favor of endovascular treatment by 
decades.
WAKE-UP trial and EXTEND trial
The efficacy and safety of MRI-based thrombolysis in Wake-Up 
stroke (WAKE-UP) and extending the time for thrombolysis 
in emergency neurological deficits (EXTEND) trials are two 
interesting addition to the literature extending the indications of 
thrombolysis beyond the traditional therapeutic window limits 
dictated by the time of onset of stroke.[15,16] WAKE-UP trial 
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studied selection of wake up ischemic stroke patients for IV 
thrombolysis based on DWI-FLAIR mismatch while EXTEND 
studied selection of ischemic stroke for IV thrombolysis based 
on automated perfusion imaging. Both trials were prematurely 
terminated. WAKE-UP trial was terminated as the funding 
got exhausted, while the EXTEND trial was stopped as the 
data and safety monitoring board (DSMB) thought that with 
the publication of positive WAKE-UP trial the EXTEND 
trial has lost clinical equipoise. WAKE-UP trial showed that 
the treatment arm is significantly better than the control in 
the primary outcome parameters, but most of the secondary 
outcomes were not significantly different after correction for 
multiple comparisons. For the primary outcome parameter of 
favorable clinical outcome of 0 or 1 on the modified Rankin 
scale (mRS) at 90 days the absolute difference between the 
arms was 11.5, giving a number needed to treat 9. In the 
EXTEND trial, the benefit was only shown in the primary 
outcome of mRS at 90 days (an absolute difference of 5.9). All 
the secondary outcomes of the study were neutral between the 
treatment and the control arms. The effect size of the EXTEND 
trial for the primary outcome was 5.9, giving a number needed 
to treat of 17.
The decision of DSMB to suggest termination of the 
EXTEND trial based on the results of the WAKE-UP trial 
seems surprising, as the studies represented different sets 
of questions. In the WAKE-UP trial, the use of an MRI 
DWI-FLAIR mismatch was intended to date the duration 
of onset of stroke. DWI-FLAIR mismatch is considered to 
predict the onset of stroke to less than 4.5 h with a moderate 
positive predictive value and a low negative predictive value. 
In the EXTEND trial, however, the perfusion defect used to 
determine the tissue viability and was considered the critical 
factor for enrolment.[16] Thus, while WAKE-UP trial used the 
NINDS-ECASS III paradigm, EXTEND used the extended 
window of therapeutic opportunity determined by perfusion 
defect. In other words, the WAKE-UP trial and EXTEND trial 
studied different paradigms. Results of the WAKE-UP trial do 
not affect clinical equipoise of the EXTEND trial. Interestingly, 
the authors of the EXTEND trial recommends another clinical 
trial to clarify the indecisive results of the study.
It appears that the idea of absence of clinical equipoise that 
made the DSMB to prematurely stop EXTEND neither existed 
before nor after the publication of the EXTEND. Thus, even 
after the publication of WAKE-UP and EXTEND trials the 
question thrombolysis in the wake-up stroke or the extended 
period after the onset of stroke is still uncertain. The results of 
prematurely terminated EXTEND only add to the uncertainty 
of the evidence in the area.
The impression of loss of equipoise EXTEND after the 
publication of the WAKE-UP trial is neither evidence-based 
nor theory-based. It is important to note that the consequence of 
“blind-alleys” of evidence left as a consequence of prematurely 
terminated large clinical studies be critically and empirically 
examined.
Tenecteplase for IV thrombolysis
Tenecteplase (TNK) is a third-generation plasminogen 
activator, with higher fibrin specificity and binding affinity 
to PAI-1. It has a 4-fold prolonged plasma half-life and 
can be administered as a single bolus. It is widely used for 
thrombolysis in myocardial infarction. Of the five trials 
published on TNK in acute ischemic stroke, the primary 
outcomes were in favor of TNK in two trials while the outcome 
was neutral for the remaining three trials.[17-22] Three of the 
neutral trials used the NINDS-rtPA trial paradigm of selecting 
patients solely using plain CT head. The two trials that showed 
benefit in favor of TNK used CT perfusion studies to select 
patients. A pooled analysis of the Australian-TNK trial and the 
subset of ATTEST (Alteplase-Teneecteplase Trial Evaluation 
for Stroke Thrombolysis) trial patients selected based on 
CT perfusion mismatch target showed that the tenecteplase 
arm has a better clinical outcome than the alteplase arm.[23] 
We would argue that ATTEST, NOR-TEST (Tenecteplase 
versus alteplase for management of acute ischemic stroke), 
Australian-TNK, and EXTEND-IA TNK (Tenecteplase versus 
Alteplase before Endovascular Therapy for Ischemic Stroke) 
trials are paradigmatically different studies and should not be 
analyzed together. In the EXTEND-IA TNK trial, the effect 
size of better recanalization of large arteries is significant 
enough for tenecteplase to prove as a better agent for bridging 
thrombolysis before endovascular intervention (22% for 
tenecteplase versus 10% for alteplase).[21] The authors in the 
latter study were prudent in choosing the recanalization rate 
as the primary outcome as the effect of thrombectomy that 
followed thrombolysis would have obscured the clinical 
difference of recanalization. This is particularly so as the 
recanalization with thrombolysis in large vessel occlusion is 
achieved in less than 10–20% of the patients and the number 
needed to show a difference would be quite large. The 
exact difference in the functional clinical outcome between 
tenecteplase and alteplase in patients selected for thrombolysis 
based on perfusion studies would be evident with the results 
of ongoing TASTE (Tenecteplase versus alteplase for stroke 
thrombolysis evaluation) trial.[24]
conclusIon
To conclude, we argue that interpretation of the results of clinical 
trials should be done looking into the finer prints of extraneous 
factors such as stopping rules, interim analysis, intricacies of 
patient selection, and the rationale of decisions that lead to 
non-prespecified termination. This can be done only by critical 
education in the art and science of interpretation of evidence 
emerging from clinical trials. The pioneering pivotal studies, 
such as NINDS rtPA and ECASS III trials, hold disproportionate 
influence in determining the contours of the subsequent fate of 
clinical trials and treatment guidelines. It needs to be recognized 
that the pooling of studies using dissimilar trial designs, 
notwithstanding similar patient profiles, would undermine the 
positive signal emerging from the studies that have used better 
selection methodologies to homogenize the study population.
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